Equities Analysts Offer Predictions for CADL FY2028 Earnings

Key Points

• HC Wainwright lowered Candel Therapeutics’ FY2028 EPS estimate to $0.69 from $0.71, while maintaining a Buy rating and $23 price target; it projects FY2029 EPS of $1.41.
• Candel reported a quarterly loss of $0.52 per share, missing the consensus estimate of a $0.27 loss by $0.25.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and average price target of $18.57, though recent insider sales and mixed ratings add caution.

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Candel Therapeutics in a report issued on Thursday, August 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn $0.69 per share for the year, down from their previous forecast of $0.71. HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Candel Therapeutics' FY2029 earnings at $1.41 EPS.

A number of other brokerages have also recently issued reports on CADL. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Candel Therapeutics in a research note on Friday, July 17th. Stifel Nicolaus initiated coverage on Candel Therapeutics in a research note on Monday, July 13th. They issued a "buy" rating and a $22.00 price target on the stock. Wall Street Zen upgraded Candel Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Cantor Fitzgerald initiated coverage on Candel Therapeutics in a research note on Monday, April 20th. They set an "overweight" rating for the company. Finally, Zacks Research raised Candel Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Friday, May 15th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Candel Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $18.57.

Candel Therapeutics Stock Performance

Candel Therapeutics stock opened at $11.80 on Friday. The company has a market cap of $864.59 million, a PE ratio of -12.04 and a beta of -0.51. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $11.87. The company's 50-day moving average is $9.62 and its two-hundred day moving average is $7.37.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.25).

Institutional Investors Weigh In On Candel Therapeutics

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its stake in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock worth $40,000 after purchasing an additional 4,439 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Candel Therapeutics in the 4th quarter valued at about $51,000. Tower Research Capital LLC TRC lifted its holdings in shares of Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after purchasing an additional 7,527 shares in the last quarter. Invesco Ltd. bought a new stake in shares of Candel Therapeutics in the first quarter valued at about $59,000. Finally, ProShare Advisors LLC acquired a new position in shares of Candel Therapeutics during the fourth quarter worth about $59,000. Institutional investors own 13.93% of the company's stock.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This represents a 23.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the transaction, the chief technology officer owned 83,865 shares in the company, valued at $840,327.30. This trade represents a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 14.30% of the company's stock.

About Candel Therapeutics

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source